2Cheitlin MD,Douglas PS,Parmley WW.26th Bethesda conference:recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities.Task Force 2:acquired valvular heart disease[J].J Am Coll Cardiol,1994,24:874-880.
3From the Centers for Disease Control and Prevention.Cardiac valvulopathy associated with exposure to fenfluramine and dexfenfluramine:US Department of Health and Human Services interim public health recommendations,November 1997[J].JAMA,1997,278:1729-1731.
4Block P.Percutaneous mitral valve repair for mitral regurgitation[J].J Interv Cardiol,2003,16:93-96.
5Condado JA,Velez-Gimon M.Catheter-based approach to mitral regurgitation[J].J Interv Cardiol,2003,16:523-534.
6Bailey LR,Luna-Guerra J,Sheahan B,et al.A percutaneous approach for the treatment of mitral regurgitation evaluated in the healthy bovine model[J].Am J Cardiol,2002,90:39H.
7Cribier A,Eltchaninoff H,Borenstein N,et al.Transcatheter unplantation of balloon-expandable prosthetic heart valve:early results in an animal model[J].Circulation,2001,104(suppl Ⅱ):Ⅱ-552.
9Cribier A,Eltchaninoff H,Bash A,et al.Percutaneous transcatheter implantation of an aortic valve prosthetic for the treatment of end-stage inoperable patients with calcifie aortic stenosis:first human case descripition[J].Circulation,2002,106:3006-3008.
10Cribier A,Eltchaninoff H,Tron C,et al.Early experience with percutaneous transcatheter implantation of heart valve prosthetic for the treatment of end-stage inoperable patients with calcifie aortic stenosis[J].J Am Coll Cardiol,2004,43:678-703.
